據報寧德時代(300750.SZ)產能利用率下滑
據內媒《第一財經》引述知情人士消息指,寧德時代(300750.SZ)知情人士透露,寧德時代產能利用率出現下滑現象。有業內人士表示,對動力電池企業而言,如何維持產線的持續運轉非常重要,故業內對於今年電池價格戰早有預料。
寧德時代今年1月份曾指,據去年半年度報告,公司電池系統產能利用率為81.25%,惟今年1月,寧德時代動力電池裝機量按年下滑12%,再加上持續擴張產能的影響,預料寧德時代產能利用率或進一步下滑。(ca/s)
~
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.